Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 8/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16669772 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL16669892 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL16669891 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL16669507 | 0.96 | CHRNB2 (0.51) | CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL16669505 | 0.96 | CHRNB2 (0.51) | CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL16669944 | 0.96 | CHRNB2 (0.51) | CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL16669639 | 0.96 | CHRNB2 (0.51) | CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL16669945 | 0.96 | CHRNB2 (0.51) | CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL16669827 | 0.96 | CHRNB2 (0.51) | CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL16669641 | 0.96 | CHRNB2 (0.51) | CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119378-A1 | AZETIDINYLOXY-, PYRROLIDINYLOXY-, AND PIPERIDINYLOXY-SUBSTITUTED METANICOTINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2015-04-30 | — | — | US | claimed |
| US-20150119378-A1 | AZETIDINYLOXY-, PYRROLIDINYLOXY-, AND PIPERIDINYLOXY-SUBSTITUTED METANICOTINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119378-A1 | AZETIDINYLOXY-, PYRROLIDINYLOXY-, AND PIPERIDINYLOXY-SUBSTITUTED METANICOTINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA5, CHRNA2, CHRNB2 | CHRNB2 3/4885CHRNA4 9/4885PIK3CD 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.